Journal of Psychopharmacology最新文献

{"title":"Neurotransmitter modulation of human facial emotion recognition.","authors":"Myrto Vlazaki, Catherine J Harmer, Philip J Cowen, Erdem Pulcu","doi":"10.1177/02698811251338225","DOIUrl":"https://doi.org/10.1177/02698811251338225","url":null,"abstract":"<p><p>Human facial emotion recognition (FER) is an evolutionarily preserved process that influences affiliative behaviours, approach/avoidance and fight-or-flight responses in the face of detecting threat cues, thus enhancing adaptation and survival in social groups. Here, we provide a narrative literature review on how human FER is modulated by neurotransmitters and pharmacological agents, classifying the documented effects by central neurotransmitter systems. Synthesising the findings from studies involving functional neuroimaging and FER tasks, we highlight several emerging themes; for example, noradrenaline promotes an overall positive bias in FER, while serotonin, dopamine and gamma-aminobutyric acid modulate emotions relating to self-preservation. Finally, other neurotransmitters including the cholinergic and glutamatergic systems are responsible for rather non-specific pro-cognitive effects in FER. With the ongoing accumulation of evidence further characterising the individual contributions of each neurotransmitter system, we argue that a sensible next step would be the integration of experimental neuropharmacology with computational models to infer further insights into the temporal dynamics of different neurotransmitter systems modulating FER.</p>","PeriodicalId":16892,"journal":{"name":"Journal of Psychopharmacology","volume":" ","pages":"2698811251338225"},"PeriodicalIF":4.5,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144086430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum: Is psychedelic use associated with cancer? Interrogating a half-century-old claim using contemporary population-level data.","authors":"","doi":"10.1177/02698811241286656","DOIUrl":"https://doi.org/10.1177/02698811241286656","url":null,"abstract":"","PeriodicalId":16892,"journal":{"name":"Journal of Psychopharmacology","volume":" ","pages":"2698811241286656"},"PeriodicalIF":4.5,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144078634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction: The effect of psychedelics on the level of brain-derived neurotrophic factor: A systematic review and meta-analysis.","authors":"","doi":"10.1177/02698811251341228","DOIUrl":"https://doi.org/10.1177/02698811251341228","url":null,"abstract":"","PeriodicalId":16892,"journal":{"name":"Journal of Psychopharmacology","volume":" ","pages":"2698811251341228"},"PeriodicalIF":4.5,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144078636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Circadian rhythmicity in prepulse inhibition of the acoustic startle response: A study of chronotype and time-of-day effects in young healthy adults.","authors":"Satyam Chauhan, Ulrich Ettinger, Kaja Fassbender, Ray Norbury, Veena Kumari","doi":"10.1177/02698811251337397","DOIUrl":"https://doi.org/10.1177/02698811251337397","url":null,"abstract":"<p><strong>Background: </strong>Prepulse inhibition (PPI) of the acoustically elicited startle response is a widely used cross-species measure of sensorimotor gating. It is known to be reduced in various psychiatric disorders. Given previous reports of (a) disrupted PPI in young adults following overnight sleep deprivation and (b) disrupted sleep-wake cycles and psychiatric disorders being more common in evening than morning chronotypes, it is possible that there are chronobiological influences on human PPI.</p><p><strong>Aims: </strong>We investigated chronotype, time of day (ToD) and synchrony effects (i.e. optimal functioning at preferred ToD) in acoustic PPI in young healthy adults.</p><p><strong>Methods: </strong>Thirty-six adults, selected from a larger pool (<i>N</i> = 213) to represent morning, intermediate or evening chronotypes, were assessed on PPI (prepulse-to-pulse intervals: 30, 60 and 120-ms) on two occasions, 1 week apart: once in the morning (8:00-10:00) and once during the late afternoon (16:00-18:00).</p><p><strong>Results: </strong>There were no chronotype or synchrony effects on PPI. In the late afternoon, compared to the morning session, (i) there was greater startle amplitude on pulse-alone trials in association with higher schizotypy and (ii) greater PPI on 120-ms (but not 30-ms or 60-ms) PPI trials, but this effect became non-significant after covarying for schizotypy.</p><p><strong>Conclusions: </strong>Our findings showed no chronotype or synchrony effect on PPI, and offer further support for PPI to be a stable biomarker that is not significantly modulated by chronotype or ToD in healthy adults. ToD, however, may influence some startle parameters in association with schizotypy and should be considered in future studies of schizotypy and related populations.</p>","PeriodicalId":16892,"journal":{"name":"Journal of Psychopharmacology","volume":" ","pages":"2698811251337397"},"PeriodicalIF":4.5,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144078632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Set and setting of psychedelics for therapeutic use in psychiatry: A systematic review.","authors":"Clémentine Estric, Thomas Duron, Sarah Kabani, Jorge Lopez-Castroman","doi":"10.1177/02698811251338214","DOIUrl":"https://doi.org/10.1177/02698811251338214","url":null,"abstract":"<p><p>Psychedelics offer promising outcomes in psychiatry. However, the preparation of participants (set) and the environmental conditions of taking a psychedelic (setting) are not standardized. We describe the set and setting for therapeutic use of psychedelic drugs in people with psychiatric disorders. In this systematic review, articles were identified in the PubMed and Web of Science databases until 12 December 2023. Only clinical trials published in English or French were eligible, and studies using psychedelics for withdrawal were excluded. Sixteen domains of set and setting were assessed covering participant selection, pre- and post-session interventions, monitor presence, environmental management, and end-of-session procedure. Of 4912 articles screened, 27 articles were retained reporting on 25 studies. Thirteen of the included studies reported randomized trials, while 12 were open-label studies, on a total of 763 participants. Studies considered features of set and setting to different extents. Participant selection and the creation of a safe environment were consistently present, but articles were more heterogeneous about reporting monitor training (52%), controlling visual distractors (64%) and creating a pleasant environment (68%). Psilocybin was over-represented (47%). Many key elements were described in each study, but differences in set and setting limit comparability and reproducibility. Harmonizing these aspects would aid the interpretation of future studies and help understand the effect of psychedelics in psychiatry.</p>","PeriodicalId":16892,"journal":{"name":"Journal of Psychopharmacology","volume":" ","pages":"2698811251338214"},"PeriodicalIF":4.5,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144005858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>CYP1A2</i> genotype-dependent effects of smoking on mirtazapine serum concentrations.","authors":"Maike Scherf-Clavel, Heike Weber, Carolin Weiß, Catherina Klüpfel, Saskia Stonawski, Leif Hommers, Stefan Unterecker, Katharina Domschke, Andreas Menke, Sarah Kittel-Schneider, Sebastian Walther, Jürgen Deckert, Angelika Erhardt-Lehmann","doi":"10.1177/02698811251337387","DOIUrl":"https://doi.org/10.1177/02698811251337387","url":null,"abstract":"<p><strong>Introduction: </strong>Psychopharmacotherapy with mirtazapine is commonplace. Lower serum concentrations of mirtazapine were reported in smokers due to <i>CYP1A2</i> induction. However, no previous study that investigated <i>CYP1A2</i> genetics and mirtazapine treatment considered <i>CYP1A2-</i>inducing parameters.</p><p><strong>Aim: </strong>We aimed to investigate the association of <i>CYP1A2</i> variants, mirtazapine serum concentration, and treatment outcome, considering the smoking status of the patients.</p><p><strong>Methods: </strong>Two depression cohorts were investigated for the association between serum concentration and treatment response of mirtazapine and <i>CYP1A2</i>-163C>A (rs762551) and -3860G>A (rs2069514) genotype groups, also considering smoking status, sex, and age of the patients. In total, 124 patients (82 non-smokers and 42 smokers) were eligible for the analyses.</p><p><strong>Results: </strong>Dose-corrected serum concentration (CD) of mirtazapine was associated with smoking status, sex, and age, with lower CD in smokers, females, and older patients. Considering non-smokers and genotype-grouped smokers, CD of mirtazapine in <i>CYP1A2</i> normal metabolizer smokers (<i>N</i> = 6) did not differ from CD of non-smokers. By contrast, smokers carrying the <i>CYP1A2</i>*1A/*1F and *1F/*1F genotype groups showed 34.4% and 33.4% lower mirtazapine CD compared to non-smokers.</p><p><strong>Discussion: </strong>As yet, for clinical practice, it may be more relevant to focus on smoking status than on the <i>CYP1A2</i> gene variants. Considering the relevant impact of smoking on the mirtazapine CD, physicians should monitor an increase in side effects due to the expected increase in mirtazapine serum concentrations. In these cases, measurement of mirtazapine CD and/or subsequent dosage reduction is recommended. The clinical relevance of <i>CYP1A2</i> genotyping prior to treatment with drugs metabolized by <i>CYP1A2</i> needs further investigation.</p>","PeriodicalId":16892,"journal":{"name":"Journal of Psychopharmacology","volume":" ","pages":"2698811251337387"},"PeriodicalIF":4.5,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144000021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effects of menthol content on the abuse liability of smokeless tobacco in a randomized crossover trial.","authors":"Eric D Claus, Jacob McDonald, Sean B Dolan, Kia J Jackson, Robert Gahl, Jia Wang, Antonio Paredes, Steven Meredith","doi":"10.1177/02698811251337367","DOIUrl":"https://doi.org/10.1177/02698811251337367","url":null,"abstract":"<p><strong>Background: </strong>Menthol is a common additive in tobacco products and reduces the aversiveness of nicotine. While numerous studies have examined the effects of menthol in cigarettes on nicotine exposure and other addiction-related outcomes, no clinical study to date has investigated the influence of menthol on nicotine pharmacokinetics (PK) and abuse liability in smokeless tobacco (ST).</p><p><strong>Aims: </strong>The current study investigated the effects of varying levels of menthol in ST on nicotine PK, pharmacodynamics (i.e., heart rate and blood pressure), hypothetical purchasing, subjective effects (e.g., withdrawal, craving, and liking), and nicotine extraction from ST.</p><p><strong>Methods: </strong>Twenty-eight male participants completed five sessions of prescribed ST use in a within-subjects, crossover design that included participants' usual-brand ST products and study ST products in which nicotine concentration was held constant and menthol levels were systematically varied: non-menthol, 1 mg of menthol per g of ST, 3 mg/g menthol, and 5 mg/g menthol.</p><p><strong>Results: </strong>No significant differences in nicotine or cotinine PK, heart rate, hypothetical purchasing, or nicotine extraction were observed between products. Subjective ratings of \"cooling\" significantly differed between the non-menthol and mentholated study products, and higher ratings of cooling were associated with greater positive subjective effects.</p><p><strong>Conclusions: </strong>These results suggest that menthol content up to 5 mg/g is unlikely to significantly impact nicotine absorption and may have a limited impact on the subjective experience of using ST.</p>","PeriodicalId":16892,"journal":{"name":"Journal of Psychopharmacology","volume":" ","pages":"2698811251337367"},"PeriodicalIF":4.5,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144025997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Brexpiprazole augmentation and mitochondrial gene expression changes in major depressive disorder.","authors":"Kohei Kondo, Yuta Yoshino, Hiroshi Kumon, Mariko Okano, Hiroaki Mori, Jun-Ichi Iga, Shu-Ichi Ueno","doi":"10.1177/02698811251337365","DOIUrl":"https://doi.org/10.1177/02698811251337365","url":null,"abstract":"<p><strong>Background: </strong>Overall, 20% of patients with major depressive disorder (MDD) are treatment-resistant and do not respond to multiple antidepressant monotherapies. For such patients, augmentation therapy with antipsychotics is one of the therapeutic options. However, the mechanism of augmentation therapy is essentially unknown.</p><p><strong>Aim: </strong>This study aimed to elucidate the mechanism of brexpiprazole (BREX) augmentation at gene expression levels.</p><p><strong>Methods: </strong>Vehicle, escitalopram (ES), BREX, and ES + BREX (augmentation therapy) were administered to mouse neuroblastoma (Neuro2a) cells and submitted to RNA-sequencing. Gene expressions were also measured in the whole blood of MDD patients and the frontal cortices and hippocampi of mice after treatment for 20 days.</p><p><strong>Results: </strong>On RNA-seq and gene ontology analyses, upregulation of mitochondria (MT)-related genes was confirmed by quantitative Polymerase Chain Reaction (PCR). These upregulated genes were successfully validated in both Neuro2a and Caco2 cells. Decreased <i>MT-ATP8</i> expression was found in the whole blood of MDD patients. Furthermore, changes in MT-mRNA expression were confirmed in the frontal cortices and hippocampi of mice with augmentation therapy.</p><p><strong>Conclusions: </strong>BREX augmentation modified MT-mRNA expressions in both in vitro and in vivo experiments. This may be a key finding in improving our understanding of MDD pathogenesis and clinical practice.</p>","PeriodicalId":16892,"journal":{"name":"Journal of Psychopharmacology","volume":" ","pages":"2698811251337365"},"PeriodicalIF":4.5,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144024853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Are the LSD-analogs lisuride and ergotamine examples of non-hallucinogenic serotonin 5-HT2A receptor agonists?","authors":"Jan Kehler, Morten Skøtt Thomsen Lindskov","doi":"10.1177/02698811251330741","DOIUrl":"https://doi.org/10.1177/02698811251330741","url":null,"abstract":"<p><p>The recent resurgence of classical psychedelic compounds, specifically 5-HT_2A receptor agonists, as potential therapeutics has led to numerous initiatives aimed at better understanding the mechanisms underlying their effects. Psychedelic compounds are commonly known as hallucinogens. One of the major outstanding questions in the field is whether altered states of consciousness-the hallucinogenic or psychedelic experience-is a prerequisite for the therapeutic effect. As a result, several academic and commercial efforts are focused on developing 5-HT_2A receptor agonists that are speculated not to have these consciousness-altering effects. However, these efforts largely rely on chemical analogs of supposedly non-hallucinogenic 5-HT_2A receptor agonists, such as lisuride and ergotamine. Our review of the literature indicates that there is no basis for claiming that lisuride or ergotamine are non-hallucinogenic at relevant concentrations in the brain. This does not invalidate current efforts to produce non-hallucinogenic 5-HT_2A receptor agonists for the potential benefit of patients, but it calls for caution in the reliance on animal data in the pursuit of such compounds and highlights the need for rigorous determination of target engagement in humans before claiming that 5-HT_2A receptor agonists are non-hallucinogenic.</p>","PeriodicalId":16892,"journal":{"name":"Journal of Psychopharmacology","volume":" ","pages":"2698811251330741"},"PeriodicalIF":4.5,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144020705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pictorial representation of illness and self measure (PRISM): A putative transdiagnostic tool for evaluating therapeutic effects of psychedelic treatments.","authors":"Niloufar Pouyan, Jacob S Aday, Steven E Harte, Chelsea M Kaplan, David A Williams, Nicolas G Glynos, Moss Herberholz, Daniel J Kruger, Julie Barron, George A Mashour, Daniel J Clauw, Katrin H Preller, Andrew Schrepf, Kevin F Boehnke","doi":"10.1177/02698811251330763","DOIUrl":"https://doi.org/10.1177/02698811251330763","url":null,"abstract":"<p><strong>Background: </strong>Patients with refractory conditions often identify themselves with their illness, which affects multiple aspects of their lives. The pictorial representation of illness and self measure (PRISM) is a tool used to assess the enmeshment of individuals' perception of self with a particular medical condition, broadly termed self-condition enmeshment.</p><p><strong>Aims: </strong>This study aimed to evaluate changes in PRISM scores and how these changes relate to symptom changes following naturalistic psychedelic use.</p><p><strong>Methods: </strong>In this survey, we retrospectively assessed changes in PRISM scores in 297 individuals who self-engaged in naturalistic psychedelic use for therapeutic purposes. Participants also completed the Patient Global Impression of Change (PGIC) scale to report symptom changes resulting from their perceived most salient psychedelic experience (MSPE).</p><p><strong>Results: </strong>PGIC scores indicated that the majority of participants with depression (95.4%), posttraumatic stress disorder (98.36%), and anxiety (94.87%) reported symptom improvement following naturalistic psychedelic use. There was a significant decrease (<i>p</i> = 4.65 × 10^-25) in PRISM scores after MSPE compared to their PRISM scores before MSPE, indicating that individuals experienced a reduced identification of their identity with their condition following psychedelic use. PRISM change scores were also correlated with PGIC scores across all conditions (ρ = 0.41, <i>p</i> = 1.64 × 10^-11), indicating that reductions in self-condition enmeshment were associated with symptom improvement.</p><p><strong>Conclusions: </strong>Our results suggest that PRISM has transdiagnostic sensitivity for investigating the effects of psychedelics on self-perception. Interpretation is limited by convenience sampling, potential positive bias, retrospective reporting, and unclear doses and settings with natural psychedelic use.</p>","PeriodicalId":16892,"journal":{"name":"Journal of Psychopharmacology","volume":" ","pages":"2698811251330763"},"PeriodicalIF":4.5,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144023043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}